Cumulative incidence of discontinued systemic treatment. (A) The cumulative incidence of discontinued systemic treatment among patients who presented NIH chronic GVHD (—) and the competing risks of death or recurrent malignancy during systemic treatment (). (B) The cumulative incidence of discontinued systemic treatment among patients who presented initially with late acute GVHD (—), together with the competing risks of death or recurrent malignancy during systemic treatment with () or without (- - -) the additional competing risk of transition to NIH chronic GVHD. Areas in each panel are labeled according to the initial event after starting treatment. The “Therapy continuing” areas include only patients without a competing event.